Arcus, Gilead to Discontinue Phase 3 Trial of Potential Cancer Treatment — Update
By Connor Hart
Arcus Biosciences and Gilead Sciences are discontinuing a Phase 3 trial of an experimental cancer treatment after an interim review showed the therapy was unlikely to help patients live longer.
Arcus said Friday that the treatment, STAR-221, failed to improve overall survival for patients with advanced gastric and esophageal cancers compared with currently available therapies.
An independent data-monitoring committee recommended that the companies stop the study due to futility.
Shares of Arcus fell 11% to $22.48 in premarket trading. Gilead's stock edged down 0.3% to $122.88.
The companies said the drug's safety profile was consistent with existing treatments and no new safety issues emerged.
Arcus and Gilead said they are working with trial investigators on next steps for patients and plan to conduct a fuller analysis of the data.
"We are disappointed with this outcome," said Arcus Chief Medical Officer Richard Markus, adding that the company remains focused on developing new treatments for cancer and immune-related diseases.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
December 12, 2025 09:27 ET (14:27 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
Why This Vanguard ETF Is One of the Best
6 ETFs To Diversify Away From AI
The Best AI Stocks to Buy Now
United States